David I. Quinn, MD, PhD, explores current approaches for managing patients with castrate-resistant prostate cancer.
Upon completion of this activity, participants should be able to:
Cancer Immunotherapy: An Online Resource for Physician Fellows and Practicing Oncologists, Edition 2
Nivolumab Active With Manageable Toxicity in Previously treated Patients With Metastatic RCC
MPDL3280A Safe and Effective in Pts With Locally Advanced or Metastatic UBC in Phase I Expansion Study
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
MPDL3280A Safe and Effective in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer in Phase I Expansion Study
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.